Finland, Russia have no serious problems in their relations — top diplomatWorld February 27, 21:49
Brazil's joyful carnivalSociety & Culture February 27, 21:30
Syrian opposition has no dialog partner seeking peace — chief negotiatorWorld February 27, 20:37
About 40 Arctic projects may be in Russia's Yamal backbone zone — governorBusiness & Economy February 27, 19:28
Russian Defense Ministry forms special purpose division near MoscowMilitary & Defense February 27, 19:13
Russian frigate in Mediterranean to deliver no strikes on terrorists in Syria — sourceMilitary & Defense February 27, 18:54
First stage of Arkhangelsk deepwater port to go operational by 2025Business & Economy February 27, 18:45
Cairo group says military option in Syria 'ruled out' after recapture of AleppoWorld February 27, 18:31
Communication breakdown between Russia and EU deters fight against real threats — MPRussian Politics & Diplomacy February 27, 17:40
TOKYO, April 16, 2014 /PRNewswire/ -- Ajinomoto Pharmaceuticals Co., Ltd. announced on April 16 that the abstract of phase 2a clinical study data of an oral alpha 4 integrin antagonist, development code AJM300, has been accepted for presentation at the Digestive Disease Week 2014 (May 3 - 6 in Chicago, USA). The contents of data will be presented at the beginning of Joint Presidential Plenary Session collaborated by the American Society for Gastrointestinal Endoscopy and the American Gastroenterological Association.
- Study data to be presented (Presentation date / time: USA Eastern time zone)
Abstract No.: 370
Title: AJM300, an Oral alpha 4 Integrin Antagonist, for Active Ulcerative Colitis: a Multicenter, Randomized, Double-Blind, Placebo- Controlled* Phase 2A Study
Presentation date / time: May 4, 2014, 1:36-1:46 PM, Oral presentation
*Randomized double-blind, placebo-controlled study
Randomized double-blind, placebo-controlled study is a method of study to objectively evaluate the efficacy of medicine. In the study, neither investigators nor patients know which the patient takes a placebo (a mimic preparation that looks like a study drug but contains no active ingredient) or the study drug.
About Ajinomoto Pharmaceuticals Co., Ltd.
Representative Director,President & CEO: Takashi Nagamachi
Headquarters, Chuo-ku, Tokyo
Hajime Ito, Corporate Planning Dept, Ajinomoto Pharmaceuticals Co., Ltd.